Vanda Pharmaceuticals on Monday rejected UK-based Cycle Pharmaceuticals' second takeover proposal, which values the drugmaker at $8 per share despite a drop in Vanda (NASDAQ:VNDA)'s stock following ...
S&P 500 bull market defies expectations with 63% gains in 2 years, led by technology sector. Top performers include Nvidia, Super Micro Computer, and Vistra Corp.